Works matching IS 13866346 AND DT 2022 AND VI 52 AND IP 3
Results: 10
Atherosclerotic cardiovascular disease in non‐metabolic nonalcoholic fatty liver disease.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 317, doi. 10.1111/hepr.13738
- By:
- Publication type:
- Article
Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 235, doi. 10.1111/hepr.13739
- By:
- Publication type:
- Article
ATF2 accelerates the invasion and metastasis of hepatocellular carcinoma through targeting the miR‐548p/TUFT1 axis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 281, doi. 10.1111/hepr.13740
- By:
- Publication type:
- Article
Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 247, doi. 10.1111/hepr.13737
- By:
- Publication type:
- Article
Predictors associated with a better response to the Japanese aluminum‐free hepatitis A vaccine, Aimmugen<sup>®</sup>, for people living with HIV.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 227, doi. 10.1111/hepr.13736
- By:
- Publication type:
- Article
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 298, doi. 10.1111/hepr.13741
- By:
- Publication type:
- Article
Screening for portopulmonary hypertension using computed tomography‐based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 255, doi. 10.1111/hepr.13735
- By:
- Publication type:
- Article
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 308, doi. 10.1111/hepr.13734
- By:
- Publication type:
- Article
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 269, doi. 10.1111/hepr.13732
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 225, doi. 10.1111/hepr.13654
- Publication type:
- Article